home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

A New Approach to Anti-Inflammatory Drug Development

  December, 30 2005 4:38
your information resource in human molecular genetics
Inducible Nitric Oxide Synthase Binds, S-Nitrosylates, and Activates Cyclooxygenase-2.
Kim, S.F., Huri, D.A. and Snyder, S.H. Science, 310, 1966-1970 (December 23, 2005).

Solomon Snyder’s laboratory has built upon earlier work showing that prostaglandin production is altered by stimulants and inhibitors to inducible nitric oxide synthase (iNOS). The new data reveal that nitrosylation activates cyclooxygenase-2 (COX-2) by increasing the apparent Vmax without altering the enzyme’s affinity for its substrate, arachidonic acid. The enzyme may be nitrosylated at many of its 13 cysteine residues, but its activation is associated specifically with nitrosylation at cysteine-526. Moreover, the nitrosylation process involves a binding of iNOS with COX-2, as the two enzymes coprecipitate with an antibody to COX-2. The binding is not dependent upon their respective enzymatic activities, as inhibitors had no effect on their coimmunoprecipitation. Moreover, expression of a COX-2 fragment (484-604), which binds to iNOS, blocks prostaglandin E2 (PGE2) formation in macrophages exposed to an inflammatory stimulus, lipopolysaccharide plus gamma-interferon. Macrophages from iNOS knockout mice provided confirmatory evidence, showing a 70% lower response, as measured by PGE2 formation, to the stimulus.

The results suggest that synergism between the nitric oxide- and prostaglandin-mediated inflammatory pathways hinges on the binding of iNOS to COX-2. Hence, creation of inhibitors to iNOS that block both this enzyme’s activity and its binding to COX-2 may prove highly effective in treating inflammatory diseases.

Message posted by: Keith Markey

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.